Name: 5-Aminolevulinic acid HCl
Brand: Selleck Chemicals
SKU: S2553
Availability: InStock
Rating: 5 (9 reviews)

Jump to

Quality Control

Batch: Purity: >97%

Cited in Nature Medicine for its top-tier quality
COA
Datasheet
SDS/MSDS

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS/MSDS

97

Related Targets	PROTAC Dyes Antineoplastic and Immunosuppressive Antibiotics ADC Cytotoxin Selection Antibiotics for Transfected Cell Antibiotics for Mammalian Cell Culture ADC Linker Molecular Glues Hydrotropic Agents Antibiotics for Plant Cell Culture
Other Others Inhibitors	Furimazine (PBI 3939) Guanidinoacetic acid Blebbistatin Polybrene (Hexadimethrine Bromide) Silibinin (NSC 651520) Palmitic acid Carbazochrome sodium sulfonate (AC-17) 4-Methylumbelliferone (4-MU) Sesamin Osthole

Solubility

In vitro
Batch:

DMSO : 34 mg/mL (202.87 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 34 mg/mL

Ethanol : 10 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.24mg/ml (1.43mM)	Taking the 1 mL working solution as an example, add 50 μL of 4.8 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.7mg/ml (10.14mM)	Taking the 1 mL working solution as an example, add 50 μL of 34 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	167.59	Formula	C₅H₉NO₃.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	5451-09-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	5-ALA hydrochloride			SMILES	C(CC(=O)O)C(=O)CN.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro

5-aminolevulinic acid (5-ALA)-Photodynamic therapy (PDT) results in down regulation of nuclear factor kappa B (NFkappaB) and baculovirus inhibitor-of-apoptosis repeat containing-3 (BIRC-3) protein. 5-aminolevulinic acid (5-ALA)-Photodynamic therapy (PDT) causes increase in Bax:Bcl-2 ratio and mitochondrial release of cytochrome c and apoptosis-inducing factor (AIF). 5-aminolevulinic acid yields reactive oxygen species upon metal-catalyzed oxidation and causes in vivo and in vitro impairment of rat liver mitochondria and DNA damage. 5-aminolevulinic acid induces a dose-dependent damage in nuclear and mitochondrial DNA in human SVNF fibroblasts and rat PC12 cells. 5-aminolevulinic acid dose-dependently decreases cAMP levels (maximal inhibition of 38%, at 1 mM), due to an inhibition of basaladenylate cyclase activity. 5-aminolevulinic acid also inhibits fluoride- and Gpp(NH)p-stimulated, but not the forskolin-stimulated adenylate cyclase activity. 5-aminolevulinic acid also inhibits the activity of adenylate cyclase in membranes isolated from rat cortex and striatum and from human cortex. 5-aminolevulinic acid (0-3mM) dose-dependently inhibits glutamate uptake by astrocyte cultures. 5-aminolevulinic acid significantly reduces both the K(m) and V(max) of glutamate uptake indicating an uncompetitive inhibition. 5-aminolevulinic acid significantly increases astrocyte lipoperoxidation in astrocytes incubated under these conditions. 5-aminolevulinic acid mediated sonodynamic therapy exhibits synergistic apoptotic effects on THP-1 macrophages, involving excessive intracellular reactive oxygen species generation and MMP loss.

References

[1] https://pubmed.ncbi.nlm.nih.gov/17335970/
[2] https://pubmed.ncbi.nlm.nih.gov/15542056/
[3] https://pubmed.ncbi.nlm.nih.gov/11099779/

[4] https://pubmed.ncbi.nlm.nih.gov/9990306/
[5] https://pubmed.ncbi.nlm.nih.gov/23426386/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06876038	NOT_YET_RECRUITING	Oral Cancer; Oral Cavity Cancer; Oral Leukoplakia; Oral Lichen Planus; Oral Squamous Cell Carcinoma	University of Massachusetts, Boston	2026-09	PHASE2
NCT05590689	RECRUITING	Glioblastoma	Universität Münster	2022-11-09	PHASE1; PHASE2
NCT02191488	ACTIVE_NOT_RECRUITING	Brain Tumors	David W. Roberts	2014-07	PHASE1
NCT06948552	RECRUITING	Upper Tract Urothelial Carcinoma	Henry Ford Health System	2026-08	PHASE2
NCT07225621	RECRUITING	Glioblastoma; GBM	Alpheus Medical, Inc.	2026-01-28	PHASE2
NCT07038278	NOT_YET_RECRUITING	Soft Tissue Sarcoma (STS)	University of Colorado, Denver	2026-09-01	EARLY_PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

5-Aminolevulinic acid HCl

Chemical Structure

Molecular Weight: 167.59